Investor's Business Daily on MSN
Why a biotech M&A wave may hit this winter
Biotech stocks have slumped from their August highs. But experts say renewed M&A, likely coming, could catalyze them.
Dublin, May 09, 2025 (GLOBE NEWSWIRE) -- The "Joint Venture Deals in Pharmaceuticals and Biotechnology 2016-2025" report has been added to ResearchAndMarkets.com's offering. Joint Venture Deals in ...
Dianthus Therapeutics (NASDAQ:DNTH) has earned its first place on Fortune’s Best Workplaces in BioPharma list, highlighting ...
Biotech and pharma organizations are adopting AI at rapid pace, focusing on R&D, and precision medicine. As challenges emerge ...
At the industry's top events, pharma professionals can dive into these issues and more through educational sessions, networking events and keynote presentations from industry leaders. Here's a look at ...
As production becomes more complex and highly regulated, digitalisation and automation are emerging as critical enablers. G ...
(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Merger and Acquisition (M&A) Deals in Pharmaceuticals, Biotechnology and Diagnostics 2021-2026" has been added to ...
December 2025 marked an exceptionally active period for life sciences regulation in the European Union (EU). Within the space of a few days, EU institutions have reached political agreement on the ...
(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Sept. 28, 2026 (GLOBE NEWSWIRE) -- "Manufacturing and Supply Deals in Pharmaceuticals and Biotechnology 2021-2026" has been added to ResearchAndMarkets.com's ...
Hosted on MSN
Vertex Pharmaceuticals just hit an all-time high. Here's why the biotech stock could soar even more
Vertex Pharmaceuticals appears likely to continue to dominate its core therapeutic area. The company is slowly developing and launching medicines in other markets. These 10 stocks could mint the next ...
Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...
How significant is FDA approval of Journavx for Vertex? Vertex CEO Reshma Kewalramani described the FDA approval of Journavx as "a historic milestone for the 80 million people in America who are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results